Crinetics Pharmaceuticals Inc
Fermé
SecteurSoins de santé
84.95 0.13
Résumé
Variation du prix de l'action
24h
Min
84.95
Max
84.95
Revenu | 7M -121M |
|---|---|
Ventes | 14M 25M |
BPA | -1.14 |
Marge bénéficiaire | -481.149 |
Employés | 594 |
EBITDA | -4.7M -131M |
Recommandations | Neutre |
|---|---|
Prévisions sur 12 Mois | +0.72% upside |
Capitalisation Boursière | 148M 9B |
|---|---|
Ouverture précédente | 84.82 |
Clôture précédente | 84.95 |
Crinetics Pharmaceuticals Inc Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
Actualités Associées
Comparaison
Variation de prix
Crinetics Pharmaceuticals Inc prévision
Objectif de Prix
By TipRanks
0.72% hausse
Prévisions sur 12 Mois
Moyen 85.56 USD 0.72%
Haut 95 USD
Bas 80 USD
Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.
Éléments financiers
$
À Propos Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
